Daily Endocrinology Research Analysis
Top endocrinology advances today span microbiome–endocrine crosstalk in polycystic ovary syndrome, definitive evidence that SGLT2 inhibitors protect kidneys across KDIGO risk strata, and a cell-specific adiponectin–PPARγ axis that restrains liver fibrosis. Together, these studies open new therapeutic targets and refine guideline-relevant practice.
Summary
Top endocrinology advances today span microbiome–endocrine crosstalk in polycystic ovary syndrome, definitive evidence that SGLT2 inhibitors protect kidneys across KDIGO risk strata, and a cell-specific adiponectin–PPARγ axis that restrains liver fibrosis. Together, these studies open new therapeutic targets and refine guideline-relevant practice.
Research Themes
- Microbiome–endocrine–immune axis in metabolic diseases
- Kidney protection with SGLT2 inhibitors across risk spectrum
- Cell-specific drivers of fibrosis and metabolic cross-talk
Selected Articles
1. The intestinal fungus Aspergillus tubingensis promotes polycystic ovary syndrome through a secondary metabolite.
Across three Chinese cohorts (n=226), the gut fungus Aspergillus tubingensis was enriched in PCOS and induced a PCOS-like phenotype upon colonization in mice by inhibiting AhR signaling and decreasing IL-22 in ILC3s. A strain-diversity metabolite screen identified AT-C1 as an endogenous AhR antagonist mediating the phenotype. This establishes a mycobiome-derived mechanism for PCOS and nominates AhR signaling restoration as a therapeutic strategy.
Impact: First mechanistic linkage of gut mycobiota and a defined fungal metabolite to PCOS via the AhR–ILC3–IL-22 axis opens a new pathogenic paradigm and drug target space.
Clinical Implications: Suggests screening the gut mycobiome in PCOS and exploring AhR pathway–modulating interventions (e.g., AhR agonists, microbiome/mycobiome modulation) as adjunctive therapies alongside lifestyle and ovulatory treatments.
Key Findings
- Aspergillus tubingensis was enriched in the gut of PCOS cohorts across three regions (total n=226).
- Colonization with A. tubingensis induced PCOS-like phenotypes in mice via inhibition of AhR signaling and reduced IL-22 from ILC3s.
- A strain-diversity-based metabolite screen identified AT-C1 as an endogenous AhR antagonist that mediated PCOS features.
Methodological Strengths
- Integration of human multi-cohort profiling with in vivo colonization models
- Mechanistic dissection of immune signaling (AhR/ILC3/IL-22) and metabolite-level causation
Limitations
- Human cohorts were restricted to three regions in China, potentially limiting generalizability.
- Causality in humans remains to be proven and metabolite exposure levels in human gut remain to be quantified.
Future Directions: Validate fungal prevalence and AT-C1 levels in diverse populations; test AhR-targeted or mycobiome-modulating therapies in PCOS; delineate dietary and environmental modifiers of the mycobiome–endocrine axis.
Polycystic ovary syndrome (PCOS) affects 6%-10% of women of reproductive age and is known to be associated with disruptions in the gut bacteria. However, the role of the gut mycobiota in PCOS pathology remains unclear. Using culture-dependent and internal transcribed spacer 2 (ITS2)-sequencing methods, we discovered an enrichment of the gut-colonizable fungus Aspergillus tubingensis in 226 individuals, with or without PCOS, from 3 different geographical areas within China. Colonization of mice with A. tubingensis led to a PCOS-like phenotype due to inhib
2. Sodium-Glucose Cotransporter 2 Inhibitors and Kidney Outcomes across the Spectrum of Kidney Disease: A Systematic Review and Meta-Analysis.
In a meta-analysis of 10 large RCTs (n=78,184; median follow-up 2.7 years), SGLT2 inhibitors reduced composite kidney outcomes across KDIGO risk categories (HR range ~0.48–0.60) and UACR strata (HR ~0.61–0.80), without heterogeneity between groups. Benefits extended to lower-risk populations, though standardization of composites varied and non-diabetic representation was limited.
Impact: Consolidates the evidence base to support broader use of SGLT2 inhibitors for kidney protection beyond high-risk CKD, informing guidelines and payer decisions.
Clinical Implications: Supports prescribing SGLT2 inhibitors for kidney protection across KDIGO classes and albuminuria levels, with careful consideration of patient profiles and outcome definitions.
Key Findings
- Meta-analysis of 10 RCTs (n=78,184) showed SGLT2 inhibitors reduced composite kidney outcomes across KDIGO low to very high risk groups (HR ~0.48–0.60).
- Benefits were consistent across UACR categories (<30, 30–300, >300 mg/g) with HRs ~0.61–0.80 and no heterogeneity between groups.
- Risk of bias was low; GRADE applied; registration CRD42023492877. Limitations include limited representation of non-diabetic low-risk populations and varying composite definitions.
Methodological Strengths
- Large-scale synthesis of randomized placebo-controlled trials with low risk of bias
- Stratified analyses across KDIGO and UACR with random-effects modeling and GRADE assessment
Limitations
- Composite kidney outcomes were not standardized across trials.
- Lower representation of non-diabetic low-risk participants limits generalization to that subgroup.
Future Directions: Harmonize outcome definitions and expand trials in non-diabetic, lower-risk cohorts; assess cost-effectiveness and implementation in diverse healthcare systems.
KEY POINTS: The effect of sodium-glucose cotransporter 2 inhibitors in preventing kidney outcomes in populations at lower risk of kidney disease remains uncertain. Pooled data from randomized controlled trials show that sodium-glucose cotransporter 2 inhibitors prevent kidney outcomes across the spectrum of kidney disease risk. BACKGROUND: Sodium-glucose cotransporter 2 (SGLT2) inhibitors have shown to reduce clinically meaningful kidney outcomes in individuals with CKD at high risk of adverse outcomes. The effect of these agents in preventing clinically meaningful kidney outcomes in populations at lower risk remains uncertain. We aim to evaluate the effect of SGLT2 inhibit
3. The adiponectin-PPARγ axis in hepatic stellate cells regulates liver fibrosis.
Using an HSC-specific inducible transgenic system (Lrat-rtTA), the authors show that HSC ablation protects against MCD diet-induced fibrosis and that HSC-specific adiponectin overexpression suppresses, while deletion accelerates, fibrosis. They define a local adiponectin–PPARγ axis in HSCs that regulates fibrosis independently of circulating adiponectin.
Impact: Reveals a cell-intrinsic adiponectin–PPARγ brake on fibrosis, shifting focus from systemic to local adipokine signaling and providing a precise antifibrotic target.
Clinical Implications: Suggests potential for HSC-targeted PPARγ activation or enhancement of local adiponectin signaling in liver fibrosis, complementing systemic metabolic therapies for NASH/NAFLD.
Key Findings
- An HSC-specific, doxycycline-inducible Lrat-rtTA line enables precise gene manipulation in stellate cells.
- HSC ablation protects against MCD diet-induced fibrosis, confirming causal involvement of HSCs.
- HSC-specific adiponectin overexpression reduces, while deletion accelerates, fibrosis via a local adiponectin–PPARγ axis independent of circulating adiponectin.
Methodological Strengths
- Cell-type–specific inducible genetic models enabling causal inference
- Concordant gain- and loss-of-function studies across in vivo fibrosis models
Limitations
- Primarily MCD diet model; validation in additional fibrosis etiologies (e.g., toxic, cholestatic) is needed.
- Translational biomarkers linking HSC-local signaling to human fibrosis progression remain to be established.
Future Directions: Test HSC-targeted PPARγ modulators and enhance local adiponectin signaling in diverse fibrosis models; develop imaging/serologic biomarkers of HSC PPARγ activity for clinical translation.
Hepatic stellate cells (HSCs) are key drivers of local fibrosis. Adiponectin, conventionally thought of as an adipokine, is also expressed in quiescent HSCs. However, the impact of its local expression on the progression of liver fibrosis remains unclear. We recently generated a transgenic mouse line (Lrat-rtTA) that expresses the doxycycline-responsive transcriptional activator rtTA under the control of the HSC-specific lecithin retinol acyltransferase (Lrat) promoter, which enables us to specifically and inducibly overexpress or eliminate genes in these cells. The inducible elimination of HSCs protects mice from methionine/choline-deficient (MCD) diet-induced liver fibrosis, confirming their causal involvement in fibrosis development. We generated HSC-specific adiponectin overexpression and null models that demonstrate that HSC-specific adiponectin overexpression dramatically reduces liver fibrosis, whereas HSC-specific adiponectin elimination accelerates fibrosis progression. We identify a local adiponectin-peroxisome proliferator-activated receptor gamma (PPARγ) axis in HSCs that exerts a marked influence on the progression of local fibrosis, independent of circulating adiponectin derived from adipocytes.